Latest research on Tenofovir

Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. [Wikipedia] In vivo tenofovir disoproxil fumarate is converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate.

Tenofovir side effects

However, the CD4+ cell count was higher in the Zidovudine group because the duration of exposure to Zidovudine in utero was shorter than that of Tenofovir (Tenofovir was more frequently initiated before pregnancy than Zidovudine). [source, 2015]
Assess the safety and efficacy of the combination of Peg-IFN with a potent NA (Entecavir or Tenofovir) to increase anti-HBe and anti-HBs seroconversion rates. [source, 2015]
Custodio et al presented data from two randomized crossover cohorts of 32 and 14 healthy volunteers in Amsterdam 2013, where they could show that in the case of combining 150 mg cobicistat and 300 mg Tenofovir (245 mg Tenofovir-DF), the Tenofovir mean (90% CI) maximum plasma concentration is increased 55% (34–78) compared to Tenofovir mean plasma concentrations without coadministration of cobicistat. [source, 2015]
The mean (90% CI) area under the curve (AUC) and trough concentrations for Tenofovir were increased 23% (16–39) and 25% (16–36), respectively. [source, 2015]
Causality assessment was carried out using the Naranjo's scale and the World Health Organization-Uppsala Monitoring Centre Criteria after which we came to a conclusion that Tenofovir was the “probable” (Naranjo's score 5) cause of this adverse drug reaction.[34] [source, 2015]
The concomitant administration of newer, more powerful NUC such as Entecavir (ETV) or Tenofovir (TDF) have enabled a decrease in the amount of administrated HBIG. [source, 2015]
Tenofovir disoproxil fumarate, and the FDCs that contain this NRTI, are generally well tolerated by HIV-infected patients with the most reported adverse events being some dizziness and gastro-intestinal discomfort (i.e., low-grade diarrhea and nausea), rarely significant enough to cause discontinuation [23, 24]. [source, 2015]
This latter protein does not seem to be affected by the PIs, however, they may increase net intestinal absorption of Tenofovir, and this may (in theory) lead to higher renal tubular cell Tenofovir levels and thereby potentially contribute to nephrotoxicity [46–48]. [source, 2015]
A similar observation was noted in the DART trial ( number, ISRCTN13968779) with no increase in congenital, renal, or growth abnormalities with in utero Tenofovir exposure [57]. [source, 2015]
Tenofovir may cause a greater degree of initial BMD loss secondary to urinary phosphate wasting and renal osteodystrophy [78]. [source, 2015]